Lion TCR

OverviewSuggest Edit

Lion TCR is a clinical-stage biotechnology company that develops TCR-T cell therapy for cancers and life-threatening infectious diseases. The Company's lead product targets hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC).

TypePrivate
HQSingapore, SG
Websiteliontcr.com

Latest Updates

Cybersecurity ratingAMore

Key People/Management at Lion TCR

Lietao Li

Lietao Li

Founder, CEO
Antonio Bertoletti

Antonio Bertoletti

Scientific Founder
Stephen Lim

Stephen Lim

COO
Show more

Lion TCR Office Locations

Lion TCR has offices in Singapore and Guangzhou
Singapore, SG (HQ)
9 Tukang Innovation Grove
Singapore, SG
61 Biopolis Dr
Singapore, SG
77 Ayer Rajah Crescent, 01
Show all (4)

Lion TCR Financials and Metrics

Summary Metrics

Lion TCR total Funding

$20 m

Lion TCR latest funding size

$20 m

Time since last funding

3 years ago

Lion TCR investors

Lion TCR's latest funding round in May 2018 was reported to be $20 m. In total, Lion TCR has raised $20 m
Show all financial metrics

Lion TCR Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Lion TCR Online and Social Media Presence

Embed Graph

Lion TCR Blogs

Lion TCR Announces Data Presentation for its lead T-cell product, LioCyx-M at EASL Digital Liver Cancer Summit 2021

SINGAPORE – February 08, 2021 – Lion TCR announces abstracts presentation at the European Association for the Study of the Liver (EASL) Digital Liver Cancer Summit 2021 on 05-06 February...

HSA approval for Phase 1 IND clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment

SINGAPORE – January 18, 2021 – Lion TCR announced today that Health Sciences Authority (HSA) has granted approval for our local open label, single-arm, single center Phase 1 Investigational New...

Lion TCR presents two abstracts of Phase 1 clinical trial data for lead product LioCyx-M at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SINGAPORE – November 10, 2020 – Lion TCR announced today that it has presented two abstracts at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 9-14....

Lion TCR was featured in the Business Times “Fighting Covid-19 with local innovations”

SINGAPORE, Jul. 8, 2020 — Lion TCR was featured in the Business Times article “Fighting Covid-19 with local innovations” dated 7 July 2020. Read more in the link here: https://www.businesstimes.com.sg/sme/fighting-covid-19-with-local-innovations...

LION TCR joins the efforts to develop new strategies for protection and treatment in COVID-19

SINGAPORE, Apr. 6, 2020 — LION TCR joins the efforts to develop new strategies for protection and treatment in COVID-19. Infection with SARS coronavirus-2 (SARS-CoV-2), the etiological agent of coronavirus...

Lion TCR was featured on Mediacorp Channel 8 Tuesday Report

SINGAPORE, Oct. 11, 2019 — Lion TCR was featured on Singapore’s Mediacorp Channel 8 in the weekly programme Tuesday Report at 8.30pm. Watch the video in the link below to...
Show more

Lion TCR Frequently Asked Questions

  • Who are Lion TCR key executives?

    Lion TCR's key executives are Lietao Li, Antonio Bertoletti and Stephen Lim.

  • Who are Lion TCR competitors?

    Competitors of Lion TCR include Oncologie, UT Health San Antonio MD Anderson Cancer Center and Adagene.

  • Where is Lion TCR headquarters?

    Lion TCR headquarters is located at 9 Tukang Innovation Grove, Singapore.

  • Where are Lion TCR offices?

    Lion TCR has offices in Singapore and Guangzhou.

  • How many offices does Lion TCR have?

    Lion TCR has 4 offices.